Immune Networks and Therapeutic Targeting of iNKT Cells in Cancer

One of the primary goals in tumor immunotherapy is to reset the immune system from tolero-genicto immunogenic - a process in which invariant natural killer T (iNKT) cells are implicated. iNKT cells develop in the thymus and perform immunosurveillance against tumor cells peripherally.When optimally stimulated, iNKT cells differentiate and display more efficient immune functions.Some cells survive and act as effector memory cells. We discuss the putative roles of iNKT cells in antitumor immunity, and posit that it may be possible to develop novel therapeutic strategies to treat cancers using iNKT cells. In particular, we highlight the challenge of uniquely energizing iNKT cell-licensed dendritic cells to serve as effective immunoadjuvants for both arms of the immune system, thus coupling immunological networks.